e-ISSN: Pending
Negative / Null Result ReportOpen accessTherapeutics. Pharmacology

Safety of using the intravenous beta-1-adrenoblocker esmolol in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention

O. A. Saygina; T. S. Sukhinina; M. A. Terenicheva; O. V. Stukalova; M. G. Chashchin; D. V. Pevsner · 2026 · Рациональная фармакотерапия в кардиологии

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Aim. To study the safety of using the intravenous beta-blocker (BB) esmolol in the early stages of ST-segment elevation myocardial infarction (STEMI) before primary percutaneous coronary intervention (PCI) based on an analysis of the incidence and clinical significance of adverse events (acute heart failure, hypotension, bradycardia, disorders of atrioventricular conduction (AV conduction), etc.) compared with the control group.Material and methods. The presented study is part of the randomized controlled trial ESMO-VASCMI (ClinicalTrials.gov NCT number 06376630) on the study of the cardioprot

Abstract by O. A. Saygina; T. S. Sukhinina; M. A. Terenicheva; O. V. Stukalova; M. G. Chashchin; D. V. Pevsner, Рациональная фармакотерапия в кардиологии (2026) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: DOAJ · DOI 10.20996/1819-6446-2025-3241